



02-05-01

RECEIPT

Attorney Docket No. 11016US05/100-236.P2.C2

2.02 TECH CENTER 1600/2900

AUG 20 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Lewis H. Lambert

Serial No. 09/696,709

Filed: October 24, 2000

For: THERAPEUTIC COMPOSITIONS
COMPRISING
BACTERICIDAL/PERMEABILITY-
INCREASING (BPI) PROTEIN
PRODUCTS

Examiner: Not yet assigned

Group Art Unit: 1651

**CERTIFICATION UNDER
37 CFR §1.10**

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Dear Sir:

Applicants respectfully request that the filing receipt for the above-identified case be corrected to include all of the applications from which priority is claimed.

In particular, please insert two priority applications (which are shown in bold) before the first claimed priority application on the Official Filing Receipt as shown below:

THIS APPLN IS A CON OF 09/303,828 05/03/1999 ABN
WHICH IS A CON OF 08/586,133 01/12/1996 5,912,228
WHICH IS A CIP OF 08/530,599 09/19/1995 ABN
WHICH IS A CIP OF 08/372,104 01/13/1995 ABN

A copy of the Official Filing Receipt reflecting all changes in red is attached hereto as
Exhibit A.

It is believed that no fees are due upon the filing of this document, however, if any fees are due, the Commissioner is hereby authorized to charge any fees which may be required as a result of filing this paper, except issue fees, to Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd.

Respectfully submitted,

Dated: February 2, 2001

Janet M. McNicholas

Janet M. McNicholas, Ph.D.
Reg. No. 32,918
Attorney for applicants

McANDREWS, HELD & MALLOY, LTD.
500 West Madison Street, 34th Floor
Chicago, IL 60661
(312) 775-8000
(312) 775-8100 (Telefacsimile)



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 20 2001

TECH CENTER 1600/2900

COMMISSIONER FOR
UNITED STATES PATENT AND TRADEMARK
WASHINGTON, D.C. 20591
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/696,709	10/24/2000	1651	790	11016US05/100-236.P2.C2		14	4

Janet M McNicholas Esq
McAndrews Held & Malloy Ltd
500 W Madison Street 34th Floor
Chicago, IL 60661

JAN 08 2001

FILING RECEIPT



OC000000005650487

Date Mailed: 01/03/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lewis H. Lambert JR., Fremont, CA ;

Continuing Data as Claimed by Applicant WHICH IS A CON OF 09/303,828 05/03/1999 AB1
THIS APPLICATION IS A CIP OF 08/586,133 01/12/1996 5,912,228
WHICH IS A CIP OF 08/372,104 01/13/1995 ABN

Foreign Applications

Title

Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products

Preliminary Class

514

Exhibit A

Data entry by : SCOTT, JOSEPH

Team : OIPE

Date: 01/03/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

- This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

